ImmunoGen Inc. (IMGN) Fundamentals

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.
SHARE INFORMATION
Market Cap$ 1,200,679,210
Shares Outstanding220,713,090
Float219,942,867
Percent Float99.65%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 69,856,000
Latest Fiscal EPS$ -0.67
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions448
Institutional Holdings Date2022-07-31
Institutional Bought Previous 3 Months21,729,114
Institutional Holdings Percent131.7%
Institutional Sold Previous 3 Months23,294,211
Insider Holdings Date2022-07-31
Insider Bought Previous 3 Months519,065
Insider Holdings Percent1.1
Insider Sold Previous 3 Months-
Insider Shares Owned2,359,531
TRADING INFO
52 Week High$ 7.77
52 Week Low$ 3.10
52 Week High Change$ -1.45
21 Day Moving Average$ 5.12
21 Day Extended Moving Average$ 4.9465
50 Day Moving Average$ 4.427
50 Day Extended Moving Average$ 4.7246
200 Day Moving Average$ 5.3083
200 Day Extended Moving Average$ 5.1179
10 Day Average Volume2,898,250
20 Day Average Volume2,680,665
30 Day Average Volume3,130,306
50 Day Average Volume3,307,432
Alpha0.006380
Beta0.9657
Standard Deviation0.202400
R20.056947
7 Day Price Change$ 0.19
7 Day Percent Change3.62%
21 Day Price Change$ 0.14
21 Day Percent Change2.64%
30 Day Price Change$ 0.83
30 Day Percent Change18.0%
Month to Date Price Change$ 0.70
Month to Date Percent Change14.77%
Quarter to Date Price Change$ 0.94
Quarter to Date Percent Change20.89%
180 Day Price Change$ 0.12
180 Day Percent Change2.26%
200 Day Price Change$ -1.05
200 Day Percent Change-16.18%
Year to Date Price Change$ -1.98
Year to Date Percent Change-26.68%

ImmunoGen Inc. (IMGN) Key Ratios

PROFITABILITY
EBIT Margin-171.6%
EBITDA Margin-169.5%
Pre-Tax Profit Margin-138.4%
Profit Margin Count-55.41%
Gross Margin52.2%
Profit Margin TOT-55.41%
INCOME STATEMENTS
Revenue$ 89,442,000
Revenue Per Share$ 0.4052
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book4.10
Total Debt To Equity0.10
Int Coverage-21.20
Current Ratio4.50
Leverage Ratio1.80
Quick Ratio4.40
Long Term Debt To Capital0.05
VALUATION MEASURES
PE Ratio-6.80
Enterprise Value$ 678,394,392
Price to Sales13.4241
Price to Free Cash-8.40
PE High Last 5 Years-4.90
Price To Book4.10
Price To Cash Flow141.00
PE Low Last 5 Years-18.90
Price to Tangible Book4.10
MANAGEMENT EFFECTIVENESS
Receivables Turnover6.70
Invoice Turnover0.00
Assets Turnover0.20
Return Assets-46.66
Return on Equity-103.55
Return on Capital-86.04

ImmunoGen Inc. (IMGN) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEOMark Joseph Enyedy
Emplyoees106
Last AuditUQ
CIK0000855654
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address830 Winter Street
Waltham, MA 2451
Websitehttps://www.immunogen.com
Facsimile-
Telephone+1 781 895-0600
Emailcourtney.okonek@immunogen.com


Your Recent History
NASDAQ
IMGN
ImmunoGen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.